<SEC-DOCUMENT>0001628280-22-012622.txt : 20220506
<SEC-HEADER>0001628280-22-012622.hdr.sgml : 20220506
<ACCEPTANCE-DATETIME>20220505160336
ACCESSION NUMBER:		0001628280-22-012622
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20220505
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220505
DATE AS OF CHANGE:		20220505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SANGAMO THERAPEUTICS, INC
		CENTRAL INDEX KEY:			0001001233
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				680359556
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30171
		FILM NUMBER:		22896097

	BUSINESS ADDRESS:	
		STREET 1:		7000 MARINA BLVD
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
		BUSINESS PHONE:		5109706000

	MAIL ADDRESS:	
		STREET 1:		7000 MARINA BLVD
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANGAMO BIOSCIENCES INC
		DATE OF NAME CHANGE:	20000208
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>sgmo-20220505.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:bf4c9fef-d557-444c-9373-64989fe167a5,g:06108bda-1f5e-4576-8ba8-28b6843c73ea,d:5653ae0c5bf04d879c5294eacd07d65e--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sgmo-20220505</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV80L2ZyYWc6MmI2MTRhYmFmYmUzNGZhNTk2NmVhNTEzMzVkNzRhNDYvdGFibGU6NDkzNGRmOTcwODMwNGU0Mjg5MjMyZWYwZDVhN2NiOWQvdGFibGVyYW5nZTo0OTM0ZGY5NzA4MzA0ZTQyODkyMzJlZjBkNWE3Y2I5ZF8yLTEtMS0xLTQyNTc3_b6a3b1ce-f12f-4af0-8592-4239e1f24c0d">May 5, 2022</ix:nonNumeric><ix:nonNumeric contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV80L2ZyYWc6MmI2MTRhYmFmYmUzNGZhNTk2NmVhNTEzMzVkNzRhNDYvdGFibGU6NDkzNGRmOTcwODMwNGU0Mjg5MjMyZWYwZDVhN2NiOWQvdGFibGVyYW5nZTo0OTM0ZGY5NzA4MzA0ZTQyODkyMzJlZjBkNWE3Y2I5ZF8zLTEtMS0xLTQyNTc3_aff82c85-0102-4f75-8bb9-d3b4ec1901ff">0001001233</ix:nonNumeric><ix:nonNumeric contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV80L2ZyYWc6MmI2MTRhYmFmYmUzNGZhNTk2NmVhNTEzMzVkNzRhNDYvdGFibGU6NDkzNGRmOTcwODMwNGU0Mjg5MjMyZWYwZDVhN2NiOWQvdGFibGVyYW5nZTo0OTM0ZGY5NzA4MzA0ZTQyODkyMzJlZjBkNWE3Y2I5ZF80LTEtMS0xLTQyNTc3_8f6d7d1b-8e05-4b83-ac9e-cf709e8abf8e">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sgmo-20220505.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i5653ae0c5bf04d879c5294eacd07d65e_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Washington, D.C. 20549</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">FORM <ix:nonNumeric contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGV4dHJlZ2lvbjoyNTc2Yzc2ZDNhNWQ0MGM0YTIxNDgyNjMxN2VlNWNmN184Ng_06f3e181-5d32-4a5c-952e-054977b842e3">8-K</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGV4dHJlZ2lvbjoyNTc2Yzc2ZDNhNWQ0MGM0YTIxNDgyNjMxN2VlNWNmN18yMzA_b6a3b1ce-f12f-4af0-8592-4239e1f24c0d">May&#160;5, 2022</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGV4dHJlZ2lvbjoyNTc2Yzc2ZDNhNWQ0MGM0YTIxNDgyNjMxN2VlNWNmN18yMzc_6e30303f-f408-4261-84db-849f1c40e54b">SANGAMO THERAPEUTICS, INC.</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exact name of registrant as specified in its charter)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:30.571%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.571%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.574%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGFibGU6MzNmZjhkMjRiOWIxNGI2YTljYmJlMjZiNzJkYTJhNGQvdGFibGVyYW5nZTozM2ZmOGQyNGI5YjE0YjZhOWNiYmUyNmI3MmRhMmE0ZF8xLTAtMS0xLTQyNTc3_696ea0bd-57b4-4373-9f30-b41b0aa4d6fe">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGFibGU6MzNmZjhkMjRiOWIxNGI2YTljYmJlMjZiNzJkYTJhNGQvdGFibGVyYW5nZTozM2ZmOGQyNGI5YjE0YjZhOWNiYmUyNmI3MmRhMmE0ZF8xLTItMS0xLTQyNTc3_24a0f2a9-d7aa-43ff-88bf-43db996b8ea8">000-30171</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGFibGU6MzNmZjhkMjRiOWIxNGI2YTljYmJlMjZiNzJkYTJhNGQvdGFibGVyYW5nZTozM2ZmOGQyNGI5YjE0YjZhOWNiYmUyNmI3MmRhMmE0ZF8xLTQtMS0xLTQyNTc3_8a22dc99-1444-4fcf-8167-b703a799893e">68-0359556</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer<br/>ID Number)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGV4dHJlZ2lvbjoyNTc2Yzc2ZDNhNWQ0MGM0YTIxNDgyNjMxN2VlNWNmN18yNTky_b1cc7bc7-1747-4c6c-bb60-fc9636fae504">7000 Marina Blvd.</ix:nonNumeric>, <ix:nonNumeric contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGV4dHJlZ2lvbjoyNTc2Yzc2ZDNhNWQ0MGM0YTIxNDgyNjMxN2VlNWNmN18yNTkz_ed82c6b1-316d-4662-8e3e-b4945cb79191">Brisbane</ix:nonNumeric>, <ix:nonNumeric contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGV4dHJlZ2lvbjoyNTc2Yzc2ZDNhNWQ0MGM0YTIxNDgyNjMxN2VlNWNmN18zMjk_c3cfc1a8-873b-4071-8b11-f667422692d6">California</ix:nonNumeric> <ix:nonNumeric contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGV4dHJlZ2lvbjoyNTc2Yzc2ZDNhNWQ0MGM0YTIxNDgyNjMxN2VlNWNmN18yNTkx_1fbbbfa2-6284-44b4-b600-9219f9bb38dd">94005</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices) (Zip Code)</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonNumeric contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGV4dHJlZ2lvbjoyNTc2Yzc2ZDNhNWQ0MGM0YTIxNDgyNjMxN2VlNWNmN18zOTI_31abfcb0-a052-4f5d-b634-1a3d62b6b1f4">510</ix:nonNumeric>) <ix:nonNumeric contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGV4dHJlZ2lvbjoyNTc2Yzc2ZDNhNWQ0MGM0YTIxNDgyNjMxN2VlNWNmN18zOTY_7f718a76-9d59-47ce-8d8b-1105b7c73d78">970-6000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Registrant&#8217;s telephone number, including area code)&#160;</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Former Name or Former Address, if Changed Since Last Report)&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.019%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGFibGU6ZjgxZWZkYzQzNmQ4NGIzOWJhZDlmMjg4ZjUwMjQ0ODkvdGFibGVyYW5nZTpmODFlZmRjNDM2ZDg0YjM5YmFkOWYyODhmNTAyNDQ4OV8wLTAtMS0xLTQyNTc3_64c23400-19fc-42e3-92d3-ca314608a739">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.019%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGFibGU6NjE2MDliN2FiZjVhNGZkYWIzMmNkZjMwYWJjZDJjN2YvdGFibGVyYW5nZTo2MTYwOWI3YWJmNWE0ZmRhYjMyY2RmMzBhYmNkMmM3Zl8wLTAtMS0xLTQyNTc3_77ff78b4-445e-4eef-aa77-4a77e5c1ef83">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:6.086%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGFibGU6NDIwYmU0Mjg5MDkwNDhiMDg5MTY2NWJjOWQxODM0MzgvdGFibGVyYW5nZTo0MjBiZTQyODkwOTA0OGIwODkxNjY1YmM5ZDE4MzQzOF8wLTAtMS0xLTQyNTc3_80442bc9-dee3-42d9-8b3b-a651749f09d8">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:6.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.681%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGFibGU6MTMyYzk0NTVjZmNjNDUyMTkwZTM2MDNkMGQxZDY1YmUvdGFibGVyYW5nZToxMzJjOTQ1NWNmY2M0NTIxOTBlMzYwM2QwZDFkNjViZV8wLTAtMS0xLTQyNTc3_06d90790-a699-4e56-a81b-832e56e91ca1">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities registered pursuant to Section&#160;12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:30.571%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.571%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.574%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGFibGU6ZTcxOWY5OTE4NDBhNGU2ZjlkOGEwY2MwYjU1YjlmMzgvdGFibGVyYW5nZTplNzE5Zjk5MTg0MGE0ZTZmOWQ4YTBjYzBiNTViOWYzOF8yLTAtMS0xLTQyNTc3_267c0f90-846b-4900-8862-71f549224635">Common Stock, $0.01 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGFibGU6ZTcxOWY5OTE4NDBhNGU2ZjlkOGEwY2MwYjU1YjlmMzgvdGFibGVyYW5nZTplNzE5Zjk5MTg0MGE0ZTZmOWQ4YTBjYzBiNTViOWYzOF8yLTItMS0xLTQyNTc3_3f9d0fd8-d3c6-40c4-a521-8a1107802552">SGMO</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGFibGU6ZTcxOWY5OTE4NDBhNGU2ZjlkOGEwY2MwYjU1YjlmMzgvdGFibGVyYW5nZTplNzE5Zjk5MTg0MGE0ZTZmOWQ4YTBjYzBiNTViOWYzOF8yLTQtMS0xLTQyNTc3_1201889c-7c00-46d1-869b-51baac46f7dd">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#160;240.12b-2 of this chapter). </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGV4dHJlZ2lvbjoyNTc2Yzc2ZDNhNWQ0MGM0YTIxNDgyNjMxN2VlNWNmN18xMDQz_e57d6918-3e9f-4e33-8b2e-9a423c9b6e62">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div style="margin-top:10pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.02 Results of Operations and Financial Condition.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;5, 2022, Sangamo Therapeutics, Inc. (&#8220;Sangamo&#8221;) issued a press release announcing its financial results for the quarter ended March 31,&#160;2022 (the &#8220;Press Release&#8221;).  </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the Press Release furnished as Exhibit&#160;99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the SEC made by Sangamo whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.01 Financial Statements and Exhibits.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exhibits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.543%"><tr><td style="width:1.0%"></td><td style="width:12.170%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.901%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.693%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit-991050522.htm">Press Release regarding financial results dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit-991050522.htm">May 5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit-991050522.htm">, 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.990%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SANGAMO THERAPEUTICS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: May 5, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ SCOTT B. WILLOUGHBY</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott B. Willoughby</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, General Counsel and Corporate Secretary</span></td></tr></table></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit-991050522.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i35fc3727d430464aabb933eb1fabebb5_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:432pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div><img alt="logoa.gif" src="logoa.gif" style="height:100px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FIRST QUARTER 2022 FINANCIAL RESULTS </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Conference Call and Webcast Scheduled for 4&#58;30 p.m. Eastern Time </font></div><div><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Brisbane, California, May 5, 2022</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Sangamo Therapeutics, Inc. (Nasdaq&#58; SGMO), a genomic medicines company, today reported recent business highlights and first quarter 2022 financial results.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;This quarter, we have continued to progress multiple programs through clinical development and demonstrated, once again, Sangamo&#8217;s track record of advancing groundbreaking therapies in genomic medicine,&#8221; said Sandy Macrae, Chief Executive Officer of Sangamo. &#8220;We dosed a total of five patients across three programs, including the first patient in our study for the treatment of kidney transplant rejection, in what we believe was the first in human dosing of an engineered CAR-Treg cell therapy product candidate. We believe this progress positions us well to advance transformational genomic medicines for patients in need and to generate long-term value for our shareholders.&#8221;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Business Highlights</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fabry disease &#8211; Dosed three additional patients, resulting in a total of nine patients dosed to date, thereby completing dose escalation for the Phase 1&#47;2 study&#59; Phase 3 planning progresses.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We dosed two patients in Cohort 4 in the Phase 1&#47;2 STAAR study evaluating isaralgagene civaparvovec, our wholly owned gene therapy product candidate for the treatment of Fabry disease, at a dose level of 5e13 vg&#47;kg.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In addition, we dosed a third patient in Cohort 3, at the dose level of 3e13 vg&#47;kg.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In total, we have successfully dosed a total of nine patients across four cohorts to complete the dose escalation portion of the study.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Enzyme replacement therapy (ERT) withdrawal was completed for a second patient, with no reports to date that the resumption of ERT is required in either patient.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We expect to provide updated results from the STAAR study in the second half of 2022.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We continue to actively prepare for the expansion cohorts, as well as a potential pivotal Phase 3 trial.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sickle cell disease &#8211; Dosed fifth patient, the first with a product candidate manufactured using improved methods&#59; Phase 3 planning progresses. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We dosed the fifth patient in the Phase 1&#47;2 PRECIZN-1 study of SAR445136, a zinc finger nuclease gene-edited cell therapy candidate for the treatment of sickle cell disease, which is under development with Sanofi. This is the first patient in the study to receive a product candidate manufactured using improved methods that have been shown in internal experiments to increase the number of long-term progenitor cells in the final product. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We plan to dose the remaining patients in this study by the end of the third quarter of 2022.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We expect to provide updated results from the PRECIZN-1 study in the second half of 2022.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 3 enabling activities and manufacturing readiness are in progress.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We continue to collaborate with Sanofi on an orderly transition of Sanofi&#8217;s rights and obligations under this program back to Sangamo on June 28.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hemophilia A &#8211; FDA lifted clinical hold&#59; Trial remains voluntarily paused&#59; Pfizer expects to resume trial in Q3 2022. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pfizer announced that, in March 2022, the FDA lifted the clinical hold that had been placed on the Phase 3 AFFINE trial of giroctocogene fitelparvovec, an investigational gene therapy we are developing with Pfizer for patients with moderately severe to severe hemophilia A. Pfizer previously paused this trial when some of the patients experienced FVIII activity greater than 150% following treatment.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pfizer also announced that the voluntary pause remains in place until all necessary conditions are met, including approval of updated trial protocols by regulatory authorities.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In addition, Pfizer announced that a patient with elevated FVIII levels reported a below-the-knee deep vein thrombosis. The patient had a history of thrombotic events prior to participation in the trial, which is a known risk factor for subsequent events and an exclusion criterion for participation in the AFFINE trial. The case was assessed to understand all potential contributing factors, including missed doses of investigator-prescribed direct oral anti-coagulants. The patient is reported to be doing well. The information was shared with trial investigators, health authorities and the independent external Data Monitoring Committee and Pfizer responded to queries from health authorities. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pfizer announced that it anticipates resuming this trial in the third quarter of 2022, with a pivotal data readout estimated in the second half of 2023. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Over 50% of the patients have been enrolled in the Phase 3 AFFINE trial.  </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Renal Transplant Rejection &#8211; Believed to be first-ever in human dosing with an engineered CAR-Treg cell therapy candidate.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We dosed the first patient in our Phase 1&#47;2 STEADFAST study evaluating TX200, our wholly owned autologous CAR-Treg cell therapy treating patients receiving an HLA-A2 mismatched kidney from a living donor. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The patient continues to do well, and no adverse events related to treatment have been reported.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Dosing of the second patient is expected around the middle of 2022, based on their transplant schedule. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We expect to complete dosing of the first cohort, comprised of three patients, by the end of 2022. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">American Society of Gene and Cell Therapy (ASGCT) &#8211; Eight abstracts accepted.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A total of eight Sangamo abstracts were accepted for presentation at ASGCT on May 16-19, 2022, including pre-clinical updates across our CAR-Treg autoimmune cell therapy platform, innovations in our genome engineering platform and advances in our AAV capsid engineering program.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">First Quarter 2022 Financial Results</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated net loss for the first quarter ended March 31, 2022 was $44.0 million, or $0.30 per share, compared to a net loss of $45.9 million, or $0.32 per share, for the same period in 2021.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues for the first quarter ended March 31, 2022 were $28.2 million, compared to $26.3 million for the same period in 2021. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $2.0 million in revenues was primarily attributed to an increase of $1.0 million related to our collaboration agreement with Novartis, an increase of $0.7 million related to our collaboration agreement with Biogen, and an increase of $0.4 million related to our collaboration agreement with Sanofi.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GAAP and Non-GAAP operating expenses</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:73.863%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.683%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In millions)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.6&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.5&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.5&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.6&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.5)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP operating expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.8&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.1&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses on a GAAP basis for the first quarter ended March 31, 2022 were $73.5 million, compared to $72.6 million for the same period in 2021. Non-GAAP operating expenses, which exclude stock-based compensation expense, for the first quarter ended March 31, 2022 were $65.8 million, compared to $65.1 million for the same period in 2021.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in total operating expenses on a GAAP basis was primarily driven by our higher preclinical, clinical and lab supply and other R&#38;D expenses along with our increased headcount to support the advancement of our clinical trials and our ongoing collaborations. Manufacturing and overhead costs also increased as we ramp up our internal manufacturing operations.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, cash equivalents and marketable securities</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and marketable securities as of March 31, 2022 were $400.3 million, compared to $464.7 million as of December 31, 2021.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Guidance for 2022 Reiterated (initial guidance provided on February 24, 2022)</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a GAAP basis, we continue to expect total operating expenses in the range of approximately $320 million to $350 million in 2022, which includes non-cash stock-based compensation expense. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to expect non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expense of approximately $40 million, in the range of approximately $280 million to $310 million in 2022.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conference Call</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo will host a conference call today, May 5,&#160;2022, at 4&#58;30&#160;p.m. Eastern Time, which will be open to the public. The call will also be webcast with live Q&#38;A and can be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under</font><font style="color:#0a2299;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Events&#160;and&#160;Presentations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conference call dial-in numbers are (877)&#160;377-7553 for domestic callers and (678)&#160;894-3968 for international callers. The conference ID number for the call is 3090098. Participants may access the live webcast via a link on the Sangamo Therapeutics website in the Investors and Media section under </font><font style="color:#0a2299;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Events&#160;and&#160;Presentations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. A conference call replay will be available for one week following the conference call. The conference call replay numbers for domestic and international callers are (855)&#160;859-2056 and (404)&#160;537-3406, respectively. The conference ID number for the replay is 3090098.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Sangamo Therapeutics</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently don&#8217;t exist. For more information about Sangamo, visit www.sangamo.com.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward-Looking Statements </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This press release contains forward-looking statements regarding our current expectations. These forward-looking statements include, without limitation, statements relating to&#58; the therapeutic and commercial potential of our product candidates, the anticipated plans and timelines of Sangamo and our collaborators for screening, enrolling and dosing patients in and conducting our ongoing and potential future clinical trials and presenting clinical data from our clinical trials, including plans for cohort expansion in, and the presentation of updated clinical data from, the Phase 1&#47;2 STAAR study and updates regarding the PRECIZN-1 study, the dosing of patients with product candidates using improved manufacturing methods in the PRECIZN-1 study and the potential impacts thereof, as well as the timing and expectations for completion of dosing in such study, plans and timing for the transition of the SAR445136 program from Sanofi to Sangamo, the expected timeline for dosing </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional patients in the STEADFAST study, the anticipated advancement of our product candidates to late-stage development including potential future Phase 3 trials, plans and timing regarding the submission of a protocol amendment in the Phase 3 AFFINE trial and the resumption of dosing of patients in and presentation of data from such trial, our 2022 financial guidance related to GAAP and non-GAAP total operating expenses and stock-based compensation, and other statements that are not historical fact. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the effects of the evolving COVID-19 pandemic and the impacts of the pandemic and other factors on the global business environment, healthcare systems and business and operations of Sangamo and our collaborators, including the initiation and operation of clinical trials&#59; the research and development process, including the enrollment, operation and results of clinical trials and the presentation of clinical data&#59; the uncertain timing and unpredictable nature of clinical trial results&#59; the unpredictable regulatory approval process for product candidates across multiple regulatory authorities&#59; reliance on results of early clinical trials, which results are not necessarily predictive of future clinical trial results, including the results of any Phase 3 trial of isaralgagene civaparvovec&#59; our limited experience manufacturing biopharmaceutical products, including the risks that we may be unable to maintain compliant manufacturing facilities, build additional facilities and manufacture our product candidates as intended&#59;   the potential for technological developments that obviate technologies used by Sangamo&#59; the potential for Sanofi and Sangamo to fail to come to agreement on appropriate transition agreements or to execute an orderly transition under their collaboration agreement&#59; the potential that Sangamo will not be able to identify and secure options or new collaborators for the SAR445136 program&#59; the potential for Sangamo to cease development of the SAR445136 program, whether due to its inability to secure options to advance the program or otherwise&#59; our lack of resources to fully develop, obtain regulatory approval for and commercialize our product candidates&#59; and our ability to achieve expected future financial performance.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">There can be no assurance that we and our collaborators will be able to develop commercially viable products. Actual results may differ materially from those projected in these forward-looking statements due to the risks and uncertainties described above and other risks and uncertainties that exist in the operations and business environments of Sangamo and our collaborators. These risks and uncertainties are described more fully in our Securities and Exchange Commission filings and reports, including in our Annual Report on Form 10-K for the year ended December 31, 2021 as supplemented by our Quarterly Report on Form 10-Q for the quarter ended March 31, 2022. Forward-looking statements contained in this announcement are made as of this date, and we undertake no duty to update such information except as required under applicable law.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-GAAP Financial Measure</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">To supplement our financial results and guidance presented in accordance with GAAP, we present non-GAAP total operating expenses, which exclude stock-based compensation expense from GAAP total operating expenses. We believe that this non-GAAP financial measure, when considered together with our financial information prepared in accordance with GAAP, can enhance investors&#8217; and analysts&#8217; ability to meaningfully compare our results from period to period and to our forward-looking guidance, and to identify operating trends in our business. We have excluded stock-based compensation expense because it is a non-cash expense that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented. This non-GAAP financial measure is in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP financial information, to more fully understand our business.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contact&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investor Relations &#38; Media Inquiries </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Louise Wilkie  &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ir&#64;sangamo.com </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">media&#64;sangamo.com </font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-more-</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELECTED CONSOLIDATED FINANCIAL DATA</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited&#59; in thousands, except per share data)</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Data&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,231&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,280&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,584&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,434&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,908&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,148&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,492&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,582&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,261)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,302)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,919)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,677)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,977)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,939)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interest</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Sangamo Therapeutics, Inc. stockholders</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,977)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,933)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.30)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.32)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,218&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,112&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Data&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br>2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br>2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and marketable securities</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,311&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464,717&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654,310&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721,923&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,522&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375,343&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">###</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>sgmo-20220505.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:bf4c9fef-d557-444c-9373-64989fe167a5,g:06108bda-1f5e-4576-8ba8-28b6843c73ea-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sgmo="http://www.sangamo.com/20220505" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.sangamo.com/20220505">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20220505_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20220505_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPageCoverPage" roleURI="http://www.sangamo.com/role/CoverPageCoverPage">
        <link:definition>0001001 - Document - Cover Page Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>sgmo-20220505_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:bf4c9fef-d557-444c-9373-64989fe167a5,g:06108bda-1f5e-4576-8ba8-28b6843c73ea-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_PreCommencementTenderOffer_83aeb9ae-4517-4d9c-8305-e50728ecd161_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_3d578294-8f59-4a49-8d97-05a1416bd31e_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_4009edf3-4131-4217-adf7-dcbbf58b6d9e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_a2457738-d0aa-4cb5-930c-7afe7eede72b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_88d4a376-a1b9-4b3e-adb6-f0da5c408dc8_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_cf5bd9a9-b227-46c0-80af-98753b0437b7_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_d9152791-ff9b-44e3-958e-8f19c22848a5_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_3d1fcc7a-8fc7-44d1-9a10-355084dc9efe_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_30555498-266a-458a-8422-7ccabd1ba562_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_fff4641b-e135-49d2-a041-de41ec989c6c_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_2d317d33-dcb6-4731-abfb-626be7ebdb79_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_044c0c7a-c6f4-45d9-b224-f95df706ac13_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_3dde9ee7-7fd3-4d98-b6e4-b3f329852a5a_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_e2026834-cc8c-49f3-9875-f7b4d4c56df4_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_e3f1b834-2c34-458a-9fbd-f4b3ead9121e_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_b021b6d3-e4b4-42ba-87bd-71d2436bef87_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_cb2ca6a6-be52-4a5e-9f31-ca7bac59d8f7_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_5a6ff256-a49c-46a6-97f2-a16bbb054465_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_a47c1493-62b0-4260-8b0a-7c78f143bdd0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_f09f1d58-018b-4583-9d84-ca78c9b85778_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_1ffcdd1b-c41f-4d47-8c3c-9b70a4341da1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_061794c7-ac26-42c4-acb3-3b0ad9c1b95b_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_900551a9-9ed2-486e-800c-4b757938960e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>sgmo-20220505_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:bf4c9fef-d557-444c-9373-64989fe167a5,g:06108bda-1f5e-4576-8ba8-28b6843c73ea-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sangamo.com/role/CoverPageCoverPage" xlink:type="simple" xlink:href="sgmo-20220505.xsd#CoverPageCoverPage"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CoverPageCoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_79928199-8a63-4c1a-9875-961015969e51" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b0796bdb-8d92-4c55-866c-8ae0a14dc197" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79928199-8a63-4c1a-9875-961015969e51" xlink:to="loc_dei_DocumentType_b0796bdb-8d92-4c55-866c-8ae0a14dc197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_dd6f6a87-15ba-46e9-b4a2-81f9e78367fc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79928199-8a63-4c1a-9875-961015969e51" xlink:to="loc_dei_DocumentPeriodEndDate_dd6f6a87-15ba-46e9-b4a2-81f9e78367fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_bc105e4f-7236-4d01-9db0-cb0d7fbec5d3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79928199-8a63-4c1a-9875-961015969e51" xlink:to="loc_dei_EntityRegistrantName_bc105e4f-7236-4d01-9db0-cb0d7fbec5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_ee3b1234-c68c-4bbe-9b7c-6bfca931d3e3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79928199-8a63-4c1a-9875-961015969e51" xlink:to="loc_dei_EntityIncorporationStateCountryCode_ee3b1234-c68c-4bbe-9b7c-6bfca931d3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_608ef6f1-cafd-4243-ac44-3aa66ad84115" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79928199-8a63-4c1a-9875-961015969e51" xlink:to="loc_dei_EntityFileNumber_608ef6f1-cafd-4243-ac44-3aa66ad84115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c32a60c9-3487-46b1-a8e6-39a93e07f0d3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79928199-8a63-4c1a-9875-961015969e51" xlink:to="loc_dei_EntityTaxIdentificationNumber_c32a60c9-3487-46b1-a8e6-39a93e07f0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_63afe016-a473-4d3e-9f67-80c163335e84" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79928199-8a63-4c1a-9875-961015969e51" xlink:to="loc_dei_EntityAddressAddressLine1_63afe016-a473-4d3e-9f67-80c163335e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f180d5b5-f60a-46ac-ac53-25e6471fd492" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79928199-8a63-4c1a-9875-961015969e51" xlink:to="loc_dei_EntityAddressCityOrTown_f180d5b5-f60a-46ac-ac53-25e6471fd492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_f635f38a-6527-4303-a808-eba27cf9d58f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79928199-8a63-4c1a-9875-961015969e51" xlink:to="loc_dei_EntityAddressStateOrProvince_f635f38a-6527-4303-a808-eba27cf9d58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_d4f062ad-1147-48bc-af22-9ff3b6cf06f2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79928199-8a63-4c1a-9875-961015969e51" xlink:to="loc_dei_EntityAddressPostalZipCode_d4f062ad-1147-48bc-af22-9ff3b6cf06f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_868d662e-5215-4ebf-987a-55fb29985427" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79928199-8a63-4c1a-9875-961015969e51" xlink:to="loc_dei_CityAreaCode_868d662e-5215-4ebf-987a-55fb29985427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_8093d23f-7d09-4be9-876f-1e3749160f29" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79928199-8a63-4c1a-9875-961015969e51" xlink:to="loc_dei_LocalPhoneNumber_8093d23f-7d09-4be9-876f-1e3749160f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_f488f002-5f8c-41e3-bb06-a61b35d675a5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79928199-8a63-4c1a-9875-961015969e51" xlink:to="loc_dei_WrittenCommunications_f488f002-5f8c-41e3-bb06-a61b35d675a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_9d224d5d-cac9-4ce5-9c45-91cc6cccb0c5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79928199-8a63-4c1a-9875-961015969e51" xlink:to="loc_dei_SolicitingMaterial_9d224d5d-cac9-4ce5-9c45-91cc6cccb0c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_bcad0cbf-da4e-4890-b744-ae563681ccce" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79928199-8a63-4c1a-9875-961015969e51" xlink:to="loc_dei_PreCommencementTenderOffer_bcad0cbf-da4e-4890-b744-ae563681ccce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_089da8b0-2c13-44a5-b3a6-584896d5120f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79928199-8a63-4c1a-9875-961015969e51" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_089da8b0-2c13-44a5-b3a6-584896d5120f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_11977c98-5989-4d12-8445-1d928fb90cfa" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79928199-8a63-4c1a-9875-961015969e51" xlink:to="loc_dei_Security12bTitle_11977c98-5989-4d12-8445-1d928fb90cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_605f5d5c-19d1-4623-bcd9-a5ced0f48829" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79928199-8a63-4c1a-9875-961015969e51" xlink:to="loc_dei_TradingSymbol_605f5d5c-19d1-4623-bcd9-a5ced0f48829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_03d28745-ac13-4d6a-b8c6-cd27e10a5fec" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79928199-8a63-4c1a-9875-961015969e51" xlink:to="loc_dei_SecurityExchangeName_03d28745-ac13-4d6a-b8c6-cd27e10a5fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_b838e0ae-d588-4d75-86de-c16eddacbe90" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79928199-8a63-4c1a-9875-961015969e51" xlink:to="loc_dei_EntityEmergingGrowthCompany_b838e0ae-d588-4d75-86de-c16eddacbe90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_68309988-3b11-45c1-820a-fb13e8d8d6f7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79928199-8a63-4c1a-9875-961015969e51" xlink:to="loc_dei_AmendmentFlag_68309988-3b11-45c1-820a-fb13e8d8d6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_7c1fb113-9fe6-4c28-86f2-88a6e0125bba" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79928199-8a63-4c1a-9875-961015969e51" xlink:to="loc_dei_EntityCentralIndexKey_7c1fb113-9fe6-4c28-86f2-88a6e0125bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>logoa.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logoa.gif
M1TE&.#EA@ -# 7   "'_"TY%5%-#05!%,BXP P$!   A^00      "P
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MQ"$' ;-E-79&/E157&_%98\ENQCT!2N% -OJI%]7 A]P.N3<.%XD-D($ 7F
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MB6 IYM;"23\1YPK1_\3.Z!,P')@DL&"$#P9ZCZ'=7*2R2BNOQ#++AQ K2"$
MK&*@! ]T<DFZD'#"*2WI6D- *@:B1&A*+36:2+>+[)P3(0;DY*T@"BCX (+Y
M?LRN+I1NFHLD,A55T[,SE^HQ._ZX@8$-'&@R2CV0G#OJNC9;U&V@*RBMCTRC
M)B!@ LQ".VZ^- W]PK*VRFP-)$<]BS2"&[J!P0H)HLHASSNK4HPQ!M@(H308
M+K!0.0)ZM*Q(,F]==*3["+SI. @Z"&$>':!9*QP!;Q"7.O32&B%8W!CR$L_=
M#J(H3!Q&&+<UG>ZK+%6GR*4).R#_I>ZF B+%3ZD'1O IA-JNT.H!IS2+M?^
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ME!:7&!@$/#MTVB8I((W;JH=$^  VJ(#P&YPQ.KX608PID9.^/$B(X#$^VRH
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M@*_I( Y:O!ZYOAI2LJ9 BN:2K,P8&-0Q)T;+0;0TJB)CO&KTH1O(1H880\R
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M_"D/0A0&&PE*4&$(8>=6#/*!*,I+1U.,5.> $S&0[ >5*;PI3G.*FC"^1H4
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M0%S/Q[F=H(3=4;"!_,R133S>CT#&60S6U6CD2AFF0:K%)^6(/V GT9!DFWI
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M8-/IC<(;$7BXF#+A%!0K+O7KIT9U@@3]7JM9 5LV;-BSY;5N?>0;0X5'KR"
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M(BZW@RQ"4 378 3RB"8Z3KXJ!S CH#+^[CK(YRC@R,)VT.=N( <7+Q0!( C
MC;?(:"LX)1AGCY^$* 5,X)/@<960#!Y!;\B0\'?FT5A^!P1.P"+J<F9D8A;3
M*RJ0Z"L@H&SRY#6M_W1=H*,O'M U?:,G2D"H$F.C+,L_4.;!8("]1"KC$D<2
M$\,_591$YNQ"P^<H\*PC0D*WP$I1HJHCMF_P--"[*F<F&\4!+BLL7"KA%NK\
MS&@\H<IT)NHHX*>FON_0C",DBDU+L^9"'K&LXF(D+F8WH0(KHV=H/L,9,4U
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M,5=BRS\49ZI&8[0 P X^:7<^\]T4MW&5\+ Z;P7T +("6XIRL'4QB?5@9("
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M1 E*FMVQPA%'4S@%^'>#!'4^QX (%J@E\GL&82 <P"PN-IY#]M*%\5S>O*4
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MI5,"3L,2.V>GX,@G4TIC9K0E9:D=X)%M?!(<;B2%]M%Q0W:$._(>@"DG"(0
M2\:E+:49"[A&1>8>=75W;F$G'P!C!#AF.\H8]0"CR_$<E4("^]BKAFA%"_H<
M*4 "=I [YJ0[S'D]^J,8P>@/'G"J=7N(%S&"_Z4J4!N( R,;/79X I%A2O0!
M"5L1P3*I3ZI2R6DB\-E=*4(2%"-=R44F"/DG[T149R)UZ303DILL@V1'M;&3
M/3EUM7*X:0(7%) A)7 >I4B18R%.L-N&1B8H3LH5YQ$R?T9X_D,Q62**IX5^
M*M1E!::N:QD<N0$1.501G;=7.[=J: $QL:&C -B7_Q[@DXG;D.>D2/\E JL8
M;W^6-"V*%@1#C+<E7TY2AD]30I1DH<>R(@S'&!Y@GNJV-PYA?83A-.O!&EV&
M+!8U(( K$TD+9!SE34VI&A5U-S>$LJVH5R!'2"+#3*V1IR7:4A,'$2JW:OOT
M.)&S&#$A A@S'710#SI!&VJ(:FZ9" J6:*!! BA0!T< @T(G+400/I^(J5/0
M#W4 ")5%6ELA/;]ZA*K1*L)G,KY&<':+Q&"EJ3B[*C7A*L$1(0OD0#8A?+(R
M157E$\OI:]:YO1H":<*60(03<%$37E]8:02B<5NZ>P 02Y[S-R34OK3((.-Q
MOQ6Q2<Z#/%H(-ZE6%A7YDO\C$R'K07HQ4:[HDEZP0AQ5"ET(X'H;=8BWHA_A
MX5,#&GJ0Z%;GM3Y\S"K+V+G\,2&RI1,ZH0$E8'VG8IQY7#D:L@;\JDP.,#I?
M,$3%$S&R!2L%0I/X\;/V*S39UDXTAF$;,3IK$'[3=*V(TUO2,P\Y$#2=&A9/
M1:P_PC\>\9@XEK.Q41!N>B7^H'_(L[3GP\9<<)'I6K3*@D *T5_=3!?6L43[
M%5+MH88Q,2@H,7[YU(Q7LA&K6'V]!1J4HCJ7H%CR< )H=A?[?"XI, 4KH()-
M1UEIYE ^P:E#,TG_\07=$V5(1;9)C-&(@\L*)QR!]L0NTM$[IS_&,9^RX@&%
M>[+_65PY$+$DD&%].? !L^=:@NR;<%*!4N(?XALF#:<0X$ 1HH%^K16BP1A.
M*Z>&R%$L.W%H74,!']!-(ZVN,1$<G?M(IV9D N5?.%L\]6>YND2(%A,9N8@K
M&Y,2'>.YWR%] 14G)S.7T=&R(V!)_P::';V#N <!A5O*)A9J+@UI"G$#W7 '
MA&-J'3T2(?8J-^  4SN%[;:F@QB+VQ=&W< 2;11-.04=09%B*<$&"@& [ $A
M%I=6@39O LP9R9B[%H6!RN(]?GC9T>@[VP%F9K5C:G4\8JV7.@0;%CF],$<Y
M9.E?%. !CO1X9($ Q:?"@<%B0[$!2\=8\O -^LC0H,'0_WI&!"<  AQ@*:OC
MSY0UC[R1$IS*<#L]?2=C*PN<T>=]142*7D:( ;YW P-6K%=R-6%!Q<-QSSJ1
M"&@ #CF0(;>R,2TM/110 B+@U,$9RK^8E!/ .6L1G+'AQ],EQA=X;G"!R^E2
M#[#RMS-62W^& -P A0=2S'"1GCE@ D&#([;!#]!P%M_:WE%"(8'LE%%"'C=[
MR%8)>:37KJ4J3/&J'02+VC_RB-R&+@]FQP#0O< ,3@_3'<O(HH!)(!T@K1]0
M >$'&57NQ1I0#QU0BG<@5)$+DQ_Q$HA,>3VQL/D&(L;D =]D:\,#,NOROO[2
M/6<4XG&!)I>53%;R)IZ<1PDQ)?\PE#;3;![_=VH3\RVXEW]O]*Y=>IJHZ2HA
ME! #.!P:E6CUBV@,L!]UXT+V)XBW^8;2,7ZG&=$(46'O"!G(C:E$4!2O@THK
M"!58, 54@&8%'>M$0 (F< )V4 L@  **14JKM- \$Y$VZ"^6)!L \P4X4-$6
MH9?)=][-;AF]F@8R!#/V*A AI>%M5&&)24N(75(CL*T0$ (:$ 3@L 9TD ,E
M0 ?I;NX50. :< 7UL*VN->U#TYL3D(0W'28Z#;#T3N\P\ %S.(\IL6_S]IO]
M5-]?$)RX@; JO;TKO9P40 >0U@%*-.T48ES1)1-DD:208S#)9L1OTS#LQTR%
MQ'K2AEK_P8L8<A72=!,<$@"CHW&8 J].3Y00$P,FFDXW!&#OM,23*2(!N.$!
M.* !XLX&:##T(6 !%@#7&.#,MI&4X8KA[O>_1@,!:7#+^=9Q):(25 EY.RAF
M-L$:&R$!)%:8#H^,P**@J<RZ3L4@S_H>^YL83]2BG15QN_>'A\>,^^Y5.H6Z
MFM' ,^,XCL>:"L%6E-Z))=! N$=>6B4S$)CV](%R5\ -?Q8!RL0-(>"HKQ88
M5)  BK4I3<$!J@0[MZ/KEZ '\H!*=H!**[ !NXX4((!*J7X4OAZV0 DM&7*#
M# <<^"UV)[9NS@[\3^H0N[E7*X+I&EYEASUFS@8;?CT"#C "_WYCA'ZC$]$?
MRCRR8Q;7Y]8.>0Y#@$YD26H7?DP3+?/@ :X<(#<A:(#%V7.<?U)>QU;N$S24
M!B(@D(<Q[R$&WS.;-@T($ 6^W/CR)4*! C<0X&   $ *APXU(+@AD. -?P,-
M:CR84(*(AA%3*(A8TN1)E"D=DFQXA6*!!P0T\KOXH"(_@0@@Y BIDL%/#Q(D
MP/C"SP&_+_XN#K1I$V$X @]L%J2*42$"K A&9*6HL68$C@4)%ETZ\."#A K9
ME/BITBT #UB_.#!XH^E2O$P'WH ! P$&'!78.J3@#0 #!0R(' 9 A,+/G_/6
M?(" P)_EL32]IM6X]XO "%/Q=EC3MO_DQ)L7,]:421"!AX8A2;ZE#: "AANY
MBPXL0("FTB^^OR#(L;*VR=D19U. <2.<:*:ZP=ZX4& $FY 0D1,&D*8>A"\/
M*([P4,*A:8=$J,C;<&G%BBXK^KEW+T_^)1"7].?7W[^__ 3Z62' ?@I<0;\C
M-C#!)(BT^P !&!QPX($O) "'L8>.TW!##COT\,,.DRN) @\J@^&!"0C(*R]^
M0NL,+^C*\BJX&:D2BR;-7IQQ1;%FQ"VZ<#YSP"\(L%-) >T 2$R$#HC2Z"Z-
M@+LAQ[%Z'&L$".JYX@,V1 "GA!QRJ( --C[XX$2;$'  KXL2BFXJ-PFR""V"
M%B@(H0(0T #_P_,8F&B@( L"*[J"$* 3@0I$ E%#[6(+ 0&FXK22'P((F$Z"
MXE*"*#8P)8   KHH''0ZKV*T<D=2H=-1QZE$>P"GC:2"ICD(KJ# (6](2K(V
M!BIPP)_5;N31KK'LJJNN&T) 0P0Z8GLL-L9^*J&",]6\<2 [\ZIJIE)W' A1
MV0YC  =([4)J(!S1(O4U]!9E"0 11KA 4(UZ"X>O<FDBSJ%=CVM4.0!*@#0\
MO&#:J"B$KN,S/08=,D("@OP*0;M;%WLH!2JZ &$%>004, 'Y#.Q8/HY+=N^]
M]_H)$, "$W!90/TVV* 3+!1M\# V,#GQ!@F*V57$18,6>FBB-P2:_X[*I(H@
MR&'% HU"%@FB<D93+\H-ZE7+6NH!4FN\X4<YPP%M. 1"&.Q(D_QL$H((FD.K
M-:\UJX@IJ+_&32L()&@2ALHD0,"*#FZ(@"(*3R664&)KRLTBBS+J*#<-VCT,
M-8M^0W>IQS]BP##C@"ZZI(9"@,"N B(X=THY/RO\AIUZXE=$:-FH3*PJBT5J
M1;F]717KK+&^Z%ZJ:;()@T0&\\9BSH_[Z0-/,?@"AK/@+I?>SIAR,@(L(4@D
M$0VX%"&'-,8,XH,K2D1 @HR4TFS0BT[W;*/?43=<@M(8&"DBU+@F*()@7;R(
MW8@LYETA<D@%<E.LST3%->BZ7:8\5QL1S?^& <U1X&;<1)8"7& $07#=2?X%
M@ ]PXS+E24%(FG4Q(ASA/?*P3\CZ81^/"<@^,)2A#%E(,I6I+$ !:B%]CG )
M$T#$8J"3'<0\<"O0?4Z)2V3BASQW*S;XS5!0RHN*F :G+]P+:E,YF-9XU[4G
M?49W8PG-6.;$%%*Q!B%M&XX%ZJ<A:<4%0ERSET7"PD4KK2XW%\#-UXBD$ ST
MQ4E4:0ZIW)00."DN1G1"2J@2HJ?L].E/SD'@E+@(J81 (%%-1$ER?O*HSR#D
M6UZAB=C @I5,O>56;$&#WYHS)*X]X%Y,NQW"]-(^^,&/)A'("U@0.9U75=(@
M-ID.ZR!@'M<AB4/_#"B!''=&J=+UZ$EVZ9K@(I:6$2AD!-LD'C<A,(++^.T+
MN)E.[FYG26,5BXO$RAU&$% :T/FI7%B3DE0.QZX..E%<\:K.E/S!RY@ +U\8
MH8,^S[,2B)3 <5/!Y.' $IH"2($-*2&)KKC#@"M(H!Y(!,"M0D($(B0@/QV3
MX<I$!B".R;!D(U,I#'>H!I0>:#Z7. ('%M28/K6%,L5[R ,Y^5.@ A5HYF$>
M7P@RR\_ "G@O:J=FA+<UWMQ)C$T1X^'V)Q"!N$J8\D,@4PA0 ."Q3@)!F,?"
M:/.3',S.+E#I#=RH5I%JH@4&$X"!P71#.X0<T $(X.6.;-*T@D45(P;!_]-"
M),> !\UM(P/;'[KRJKF>W.^G[Q)=1;AV+6)IT2:7<>!;H(6#;-;U;5&Y%S]^
M(Z6PM+->>@G/F[JZE*P2!&O\@,%E+%"!?"IIF0Q(JP2&$Y-*^6Z,O/L"-+IQ
M@>H@I*YV.^ %^.(DPC5';&BAR5TQ!Z5ZU7(I6,%M0R28/["8DYH:04 BT"-!
M#NUJ#5]K;"@M IXIZ8LG.,VM6QY8 K?%2)1V"DY=%5;?V0PQ8%<P3X8 D"L%
M@!0$&X"A?&[84@>7[(41]A@,[6/2 ^$PPS$[PA%NFAAOM 4B00!';@4<5!2G
MF(D_N4('IJ?%T)0Q.#RZ)73LV%C!>4M^5156*?]+Y4OA2;5]P,73<$9PA6AU
MB %LJ(>+T0)6A*B(E# B9J125&2Y/4<J4GD>[V!TN$.N]L:7W0B>1K GU[%X
MH%29#O#^^1F%5,"G*X[()PF75\-])JP[Z:1QZBPM#8S "LVQ"P'"P8\@\<,?
M3I6MG+K*/H*1LD>^-%89&:U.*WS! B4^C':2E#SDY+8ALNM*<,0F'*F!67Y2
MV1DTH($0NB:$EP7H2UZOTFB(E@Z7_I,FZH#G2V\1)UP_P<'HX(R4-SL'.F6K
M+P$;8@2*U*[0;GTHGPWJW=F4  *F763[6H26_V['S]#J2<4"3((5U$(>71"0
M@VN84H^E-&3SIN&\<9@80X[1YT"7Z$<M0& "DH2X(4B$"$<-K&*$_R=\F259
MCKA*4 \+@.<@653V>&$;GHDS.IB :O24+Y<[8#=-1^T;<@0J]=6_PB 1/%&,
M3S>%DEM1AC=0J908!X756O;()B@WW:!,>ZX(\+*O5M.-574LFL .UKTWB%Q#
M=C5)40UGY+Q1B @8 Y&*!K4E$,  3$C%/CK*A&P\Z=?!!7PK"I#+>>$16S@>
MR@_&4J_15Q3L:N?6<:UU:VX/@ $W<&N8V?Q,)65/#V+]P3:P1B6-G8&T6 "*
M)A7YAN^"$OI8[ F3)V-^\3CNW>*_!:X.@A<I<<?J0"YCWK9D79^]&D%SAG.[
MWIB>(J?K;- D.+H*MFDJMZO.!B/)<)PJRO\D1%! @A4,@@2H88<J0]F%/T;A
ME4IXAA*^1(,;_,(8)D >M4"!"4"J ,,L9HA)FK/"S7]^E%!,7&F @ 783#!$
M&\M4]=*6,+=(, I1=<S.$:/-$TGQJJ(EI7FRK^&SS3&KMT@PP\ HK!">K_HJ
MAZJ78H*_\"J(17. !5"T<SF753FZU,F+NZ"3+\A B%((-(LG<B$(L;.="SJ*
M1Y*S9E,B]&* N" =@9"ZLB@ 2L$(:SN)BGJYCNJH%"B!0).X@(J)&0DY58$J
M^<,Q?N BL, BF6B-6DJ("IB'AB ^ TN!7.&0Q#@,.@ E=)$)'4RU&N&E*@D.
M%VF1HLC #7P__NO_#;#"BZF9B?K3L>' +>,@MGG*I3);%]A B1BD*,80@<4A
M"Z]J#:) '00HJ(,[#B09H(A0J**X%ZMPBBE!@&_3(*O+IZP['HI"C,:@ B]0
M-WG@-Y )F0=;J1B2MY&IMU=<(5=LMPSKARY0 YJR*9P"/'Y)(O3[16!T"P'+
M@42 &+TXBV%"'<[;'U%IQL,)*X_#G%N:M#,\E?L+.O_)D_)ZH\8H/@V1( :8
MAP_H +((NBK[P-72+K+ D0Q<M 7(1-6ZPVD*#7ZP@F[PP*20D[1@B'P"KXT
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M#@0%/@.##"(P@3J0CR[(!P[H!PZ0T0F[/N>CL'<]*0,ID.FCT1RJO@K;  X
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M /\;<J"2; 64/I_=K!"?&1%Z3N1-.:B RCY@W ]HX+C&K6T:^N>7!NXN(D3
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MS1% 2BG&>?"&1"I$?A'F<OY%A.@,B02)CE@'&]!'C]Z8?J9JL1KKL2+KF#(
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M30S0[!8(3Q;#3T*BPV)/(31C?Z $4+JM>FP.9GJE9_KC:_2@.^S-?18"04!
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M!A^_#]-<A9BPT!OM0#UD[XPZR>]B8RH9 \[,)N1$(I=FPVI.XVA(0#.Z8,[
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AW=5?'=9C7=9GG=9KW=9O'==S7==WG==[W==_/7 " @ [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140600206061464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page Cover Page<br></strong></div></th>
<th class="th"><div>May 05, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  05,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SANGAMO THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">68-0359556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7000 Marina Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Brisbane<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">970-6000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SGMO<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001001233<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>sgmo-20220505_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="sgmo-20220505.xsd" xlink:type="simple"/>
    <context id="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <dei:DocumentPeriodEndDate
      contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV80L2ZyYWc6MmI2MTRhYmFmYmUzNGZhNTk2NmVhNTEzMzVkNzRhNDYvdGFibGU6NDkzNGRmOTcwODMwNGU0Mjg5MjMyZWYwZDVhN2NiOWQvdGFibGVyYW5nZTo0OTM0ZGY5NzA4MzA0ZTQyODkyMzJlZjBkNWE3Y2I5ZF8yLTEtMS0xLTQyNTc3_b6a3b1ce-f12f-4af0-8592-4239e1f24c0d">2022-05-05</dei:DocumentPeriodEndDate>
    <dei:EntityCentralIndexKey
      contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV80L2ZyYWc6MmI2MTRhYmFmYmUzNGZhNTk2NmVhNTEzMzVkNzRhNDYvdGFibGU6NDkzNGRmOTcwODMwNGU0Mjg5MjMyZWYwZDVhN2NiOWQvdGFibGVyYW5nZTo0OTM0ZGY5NzA4MzA0ZTQyODkyMzJlZjBkNWE3Y2I5ZF8zLTEtMS0xLTQyNTc3_aff82c85-0102-4f75-8bb9-d3b4ec1901ff">0001001233</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV80L2ZyYWc6MmI2MTRhYmFmYmUzNGZhNTk2NmVhNTEzMzVkNzRhNDYvdGFibGU6NDkzNGRmOTcwODMwNGU0Mjg5MjMyZWYwZDVhN2NiOWQvdGFibGVyYW5nZTo0OTM0ZGY5NzA4MzA0ZTQyODkyMzJlZjBkNWE3Y2I5ZF80LTEtMS0xLTQyNTc3_8f6d7d1b-8e05-4b83-ac9e-cf709e8abf8e">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGV4dHJlZ2lvbjoyNTc2Yzc2ZDNhNWQ0MGM0YTIxNDgyNjMxN2VlNWNmN184Ng_06f3e181-5d32-4a5c-952e-054977b842e3">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGV4dHJlZ2lvbjoyNTc2Yzc2ZDNhNWQ0MGM0YTIxNDgyNjMxN2VlNWNmN18yMzA_b6a3b1ce-f12f-4af0-8592-4239e1f24c0d">2022-05-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGV4dHJlZ2lvbjoyNTc2Yzc2ZDNhNWQ0MGM0YTIxNDgyNjMxN2VlNWNmN18yMzc_6e30303f-f408-4261-84db-849f1c40e54b">SANGAMO THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGFibGU6MzNmZjhkMjRiOWIxNGI2YTljYmJlMjZiNzJkYTJhNGQvdGFibGVyYW5nZTozM2ZmOGQyNGI5YjE0YjZhOWNiYmUyNmI3MmRhMmE0ZF8xLTAtMS0xLTQyNTc3_696ea0bd-57b4-4373-9f30-b41b0aa4d6fe">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGFibGU6MzNmZjhkMjRiOWIxNGI2YTljYmJlMjZiNzJkYTJhNGQvdGFibGVyYW5nZTozM2ZmOGQyNGI5YjE0YjZhOWNiYmUyNmI3MmRhMmE0ZF8xLTItMS0xLTQyNTc3_24a0f2a9-d7aa-43ff-88bf-43db996b8ea8">000-30171</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGFibGU6MzNmZjhkMjRiOWIxNGI2YTljYmJlMjZiNzJkYTJhNGQvdGFibGVyYW5nZTozM2ZmOGQyNGI5YjE0YjZhOWNiYmUyNmI3MmRhMmE0ZF8xLTQtMS0xLTQyNTc3_8a22dc99-1444-4fcf-8167-b703a799893e">68-0359556</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGV4dHJlZ2lvbjoyNTc2Yzc2ZDNhNWQ0MGM0YTIxNDgyNjMxN2VlNWNmN18yNTky_b1cc7bc7-1747-4c6c-bb60-fc9636fae504">7000 Marina Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGV4dHJlZ2lvbjoyNTc2Yzc2ZDNhNWQ0MGM0YTIxNDgyNjMxN2VlNWNmN18yNTkz_ed82c6b1-316d-4662-8e3e-b4945cb79191">Brisbane</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGV4dHJlZ2lvbjoyNTc2Yzc2ZDNhNWQ0MGM0YTIxNDgyNjMxN2VlNWNmN18zMjk_c3cfc1a8-873b-4071-8b11-f667422692d6">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGV4dHJlZ2lvbjoyNTc2Yzc2ZDNhNWQ0MGM0YTIxNDgyNjMxN2VlNWNmN18yNTkx_1fbbbfa2-6284-44b4-b600-9219f9bb38dd">94005</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGV4dHJlZ2lvbjoyNTc2Yzc2ZDNhNWQ0MGM0YTIxNDgyNjMxN2VlNWNmN18zOTI_31abfcb0-a052-4f5d-b634-1a3d62b6b1f4">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGV4dHJlZ2lvbjoyNTc2Yzc2ZDNhNWQ0MGM0YTIxNDgyNjMxN2VlNWNmN18zOTY_7f718a76-9d59-47ce-8d8b-1105b7c73d78">970-6000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGFibGU6ZjgxZWZkYzQzNmQ4NGIzOWJhZDlmMjg4ZjUwMjQ0ODkvdGFibGVyYW5nZTpmODFlZmRjNDM2ZDg0YjM5YmFkOWYyODhmNTAyNDQ4OV8wLTAtMS0xLTQyNTc3_64c23400-19fc-42e3-92d3-ca314608a739">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGFibGU6NjE2MDliN2FiZjVhNGZkYWIzMmNkZjMwYWJjZDJjN2YvdGFibGVyYW5nZTo2MTYwOWI3YWJmNWE0ZmRhYjMyY2RmMzBhYmNkMmM3Zl8wLTAtMS0xLTQyNTc3_77ff78b4-445e-4eef-aa77-4a77e5c1ef83">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGFibGU6NDIwYmU0Mjg5MDkwNDhiMDg5MTY2NWJjOWQxODM0MzgvdGFibGVyYW5nZTo0MjBiZTQyODkwOTA0OGIwODkxNjY1YmM5ZDE4MzQzOF8wLTAtMS0xLTQyNTc3_80442bc9-dee3-42d9-8b3b-a651749f09d8">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGFibGU6MTMyYzk0NTVjZmNjNDUyMTkwZTM2MDNkMGQxZDY1YmUvdGFibGVyYW5nZToxMzJjOTQ1NWNmY2M0NTIxOTBlMzYwM2QwZDFkNjViZV8wLTAtMS0xLTQyNTc3_06d90790-a699-4e56-a81b-832e56e91ca1">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGFibGU6ZTcxOWY5OTE4NDBhNGU2ZjlkOGEwY2MwYjU1YjlmMzgvdGFibGVyYW5nZTplNzE5Zjk5MTg0MGE0ZTZmOWQ4YTBjYzBiNTViOWYzOF8yLTAtMS0xLTQyNTc3_267c0f90-846b-4900-8862-71f549224635">Common Stock, $0.01 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGFibGU6ZTcxOWY5OTE4NDBhNGU2ZjlkOGEwY2MwYjU1YjlmMzgvdGFibGVyYW5nZTplNzE5Zjk5MTg0MGE0ZTZmOWQ4YTBjYzBiNTViOWYzOF8yLTItMS0xLTQyNTc3_3f9d0fd8-d3c6-40c4-a521-8a1107802552">SGMO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGFibGU6ZTcxOWY5OTE4NDBhNGU2ZjlkOGEwY2MwYjU1YjlmMzgvdGFibGVyYW5nZTplNzE5Zjk5MTg0MGE0ZTZmOWQ4YTBjYzBiNTViOWYzOF8yLTQtMS0xLTQyNTc3_1201889c-7c00-46d1-869b-51baac46f7dd">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="ia65d497963564f6683a4715b84b56ec6_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjU2NTNhZTBjNWJmMDRkODc5YzUyOTRlYWNkMDdkNjVlL3NlYzo1NjUzYWUwYzViZjA0ZDg3OWM1Mjk0ZWFjZDA3ZDY1ZV8xL2ZyYWc6MjU3NmM3NmQzYTVkNDBjNGEyMTQ4MjYzMTdlZTVjZjcvdGV4dHJlZ2lvbjoyNTc2Yzc2ZDNhNWQ0MGM0YTIxNDgyNjMxN2VlNWNmN18xMDQz_e57d6918-3e9f-4e33-8b2e-9a423c9b6e62">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M='@//GL?)=-[*CG_5U/\!%!+ P04    " !Q@*54EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( '& I53E:(KL.0$
M #("   /    >&PO=V]R:V)O;VLN>&ULC5'1;L(P#/R5*A^PEFE#&J*\@+8A
M31L:$^^A=:E%$E>."QM?/[=5!=)>]F3[;%WN+O,S\7%/=$R^O0LQ-[5(,TO3
M6-3@;;RC!H)N*F)O14<^I+%AL&6L <2[]#[+IJFW&,QB/G)M.+T=2* 0I*!@
M!^P0SO&Z[\;DA!'WZ%!^<M/W#DSB,:#'"Y2YR4P2:SJ_$N.%@EBW+9B<R\UD
M6.R !8L_\+83^67WL4?$[C^M"LG--%/""CE*?]'S6]5X CT>IE;H&9T KZS
M"U/;8#AT-.HBO;'1YS#6(<09_R=&JBHL8$5%ZR'(D".#ZP2&6&,331*LA]PL
MZ02<;.P!DFO;^=,'U^7@553D37(\0UWPNASDCAI+J#! ^:ZT47'-J]APTI6>
MY_[A<?*DN;3.+17["&]DR]'R^%V+7U!+ P04    " !Q@*54)!Z;HJT   #X
M 0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( '& I50YLI'<[0   "L"   1
M          "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( '&
MI5297)PC$ 8  )PG   3              "  <L!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ <8"E5&'CPK4]!   0!   !@
M ("!# @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( '&
MI52?H!OPL0(  .(,   -              "  7\,  !X;"]S='EL97,N>&UL
M4$L! A0#%     @ <8"E5)>*NQS     $P(   L              ( !6P\
M %]R96QS+RYR96QS4$L! A0#%     @ <8"E5.5HBNPY 0  ,@(   \
M         ( !1!   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( '& I50D
M'INBK0   /@!   :              "  :H1  !X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( '& I51ED'F2&0$  ,\#   3
M      "  8\2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(
' -D3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="sgmo-20220505.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CoverPageCoverPage</Role>
      <ShortName>Cover Page Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="sgmo-20220505.htm">sgmo-20220505.htm</File>
    <File>exhibit-991050522.htm</File>
    <File>sgmo-20220505.xsd</File>
    <File>sgmo-20220505_lab.xml</File>
    <File>sgmo-20220505_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "sgmo-20220505.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "sgmo-20220505.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sgmo-20220505_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sgmo-20220505_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "sgmo-20220505.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "sgmo",
   "nsuri": "http://www.sangamo.com/20220505",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220505.htm",
      "contextRef": "ia65d497963564f6683a4715b84b56ec6_D20220505-20220505",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page Cover Page",
     "role": "http://www.sangamo.com/role/CoverPageCoverPage",
     "shortName": "Cover Page Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20220505.htm",
      "contextRef": "ia65d497963564f6683a4715b84b56ec6_D20220505-20220505",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001628280-22-012622-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-012622-xbrl.zip
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M.6(3X)0?\U"B#\<3@+/:I1C N$*]*D0*ZD6))Y1[AB;D]Z8R\3LL]60V7O$
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M6D@3.MVCGUKE',IZATZ5C;NUR2K[AK6,J/J9*0TKHVPHV00]Q3-+E0(&S8@
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MV:@DUNO7K[>Y6-M>/W!NX)]1[+GO_A]02P,$%     @ <8"E5 S!^14E%@
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M5PX.IM-I&;Z7^_'E@1\%?D3HB ^R!$>I%R<ASF!&#D1>4#A>YR2A5+0SLY/
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MN!LH[IV#TI)GN+SGZIPK.2HG\X[,8444.!T+ J_IO*@H(JP=3\WF3BMW6OE
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M=#PC8>$JE'D1M4@Z"3)V[K0)>EAL;X(VH9,K1:O&H/CT07D3H3"62QF "^!
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M&IM/2(:3-<CUB^XX'=BQ.X>_!ED8'/X_4$L#!!0    ( '& I53X)G+2=@(
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MIQL9RW0%%4&Z,";CC9Q;*Z7JV''6Z[6]]FTN"F?LNI[S^&7YHX5:';:D[&F
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M9N'LSS_.O_(K>4U!FBU+FG$SP3)]N:P^/,\Y+2O.#^+R.D>8O\!F&# ? 1@
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MB:T-_K;86K_OV\']D/&\N,F+:B6IVFEYEM]F9?&PTB!2D!D-!ASA52>7*":
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M\7-]].;%YI-T]=KQ-R_^#U!+ P04    " !Q@*54?'7-LJ@&   !,0  %0
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M,#(R,#4P-2YH=&U02P$"% ,4    " !Q@*54^"9RTG8"  "5!P  $0
M        @ %I-@  <V=M;RTR,#(R,#4P-2YX<V102P$"% ,4    " !Q@*54
M6D.TJGP*  !$7@  %0              @ $..0  <V=M;RTR,#(R,#4P-5]L
M86(N>&UL4$L! A0#%     @ <8"E5'QUS;*H!@   3$  !4
M ( !O4,  '-G;6\M,C R,C U,#5?<')E+GAM;%!+!08     !0 % $<!  "8
%2@     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
